-->

Tag: remestemcel-L FDA approval

Home / remestemcel-L FDA approval

Categories

Remestemcel-L-rknd is approved by the USFDA for steroid-refractory acute graft versus host disease in pediatric patients

On December 18, 2024, the Food and Drug Administration sanctioned remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-r...
remestemcel-l-fda-approval

Scan the code